In Depth 20 Oct 2022 Opportunities and challenges for cell and gene therapy investments Companies in the cell and gene therapy space are struggling to raise investments amid adverse market conditions. However, this could be an opportunity for the strongest companies and investors to shine. After several years of record-breaking investments, funding is hard to come by in the gene and cell therapy space. Part of this trend relates […] October 20, 2022 - 9 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 20 Oct 2022 Tiziana Life Sciences looks to phase 1 trial for intranasal Alzheimer’s drug Tiziana Life Sciences Ltd. says it plans to submit an investigational new drug (IND) application for a phase 1 trial of intranasal foralumab in Alzheimer’s disease patients. It comes after the company received an affirmative written response from the FDA on a pre-investigational new drug application (PIND). Tiziana plans on filing the IND for Alzheimer’s […] October 20, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Oct 2022 Spanish research institution to use Elicera Therapeutics’ iTANK platform Elicera Therapeutics AB has entered a material transfer agreement with the Josep Carreras Leukaemia Research Institute (JCLRI) in Spain for use of the iTANK platform in arming CAR T-cells for the treatment of Ewing Sarcoma. Sweden’s Elicera is a clinical stage cell and gene therapy company developing next generation immuno-oncological treatments based on enhanced oncolytic […] October 20, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Oct 2022 AbbVie acquires LifeArc portfolio company DJS Antibodies AbbVie has acquired LifeArc’s portfolio company DJS Antibodies Limited, a privately-held UK-based biotechnology company dedicated to discovering and developing antibody medicines that target difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs). DJS’s lead program is DJS-002, a potential first-in-class lysophosphatidic acid (LPA) receptor 1 (LPAR1) antagonist antibody currently in investigational preclinical studies for the […] October 20, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Oct 2022 Partnership formed to make drug for MoCD Type A available sooner Inceptua Early Access and Sentynl Therapeutics Inc., a U.S.-based biopharmaceutical company bringing therapies to patients living with rare diseases, have entered into a partnership. The partnership is to make Sentynl’s Nulibry available via an early access program for eligible patients with molybdenum cofactor deficiency (MoCD) Type A. MoCD Type A is a rapidly progressive autosomal […] October 20, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 20 Oct 2022 Healthy volunteer study for tablet to treat brain cancer open for recruitment A clinical stage drug company developing sulforaphane-based medicines for cancer treatment has started recruiting for a pharmacokinetic / pharmacodynamic trial in healthy volunteers (HV). Evgen Pharma plc also announced the start an investigator sponsored clinical study (ISS) for a glioblastoma program. The purpose of the HV study is to examine the performance of Evgen’s new […] October 20, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 20 Oct 2022 Alvotech and JAMP Pharma add two biosimilar candidates for Canadian market Alvotech and the JAMP Pharma Group have expanded their exclusive partnership to commercialize biosimilars developed and manufactured by Alvotech. The companies have added two biosimilar candidates from Alvotech’s pipeline: AVT16, a proposed biosimilar to an undisclosed immunology product and AVT33, a proposed biosimilar to an undisclosed oncology product. “We are very pleased to be expanding […] October 20, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Oct 2022 C4XD and HitGen to collaborate on inflammation hit identification project Drug discovery company C4X Discovery Holdings plc and HitGen Inc., which develops DNA-encoded library (DEL) technology, are to collaborate on identifying novel, small molecule hits against an inflammatory target for further C4XD development. The aim of the project is to augment C4XD’s pipeline of small molecule inflammatory disease candidates for pre-clinical development and out-licensing to […] October 20, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Oct 2022 The role of long-read sequencing in validating CRISPR outcomes Neil Ward, general manager of PacBio EMEA With applications of CRISPR across the spectrum of microbial, plant and gene therapy increasingly being realised, enthusiasm from the research community for this technology is not expected to wane. It has the potential to, among other applications, create knock-out animal models for use in research, revolutionise agriculture and […] October 20, 2022 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 20 Oct 2022 Enhanc3D Genomics raises £10M to advance technology platform Enhanc3D Genomics, a functional genomics company, has raised £10 million ($11.2 million) in series A financing. The funds will be used to accelerate the development of its proprietary technology platform – GenLink3D. The financing was led by BGF and Parkwalk Advisors, with support from existing private investors and Bioqube Ventures. The funding will enable Enhanc3D […] October 20, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Oct 2022 VectorBuilder raises funds for gene delivery R&D VectorBuilder Biotechnology (Guangzhou) Co., Ltd., a gene delivery enterprise, has completed a series C round with CNY410 million ($56.7 million). The funding was co-led by Legend Capital. The proceeds will help VectorBuilder promote the upgrading and capacity expansion of its gene delivery R&D and production technology platform, further accelerate its global business presence, and boost […] October 20, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Oct 2022 License from Helmholtz Munich will enable progression of brain cancer treatment A treatment for one of the most aggressive and difficult to treat cancers is the focus of a licensing option that has been executed by Isotope Technologies Munich SE (ITM). The license from Helmholtz Munich was announced yesterday (October 19). The targeted radionuclide therapy with ITM-31 targets a specific protein (antigen) called CA XII, which […] October 20, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email